Clinical Trial Update: A Study of Ruxolitinib and Duvelisib in People With Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of ruxolitinib and duvelisib in patients with T-cell and NK-cell lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Lymphoma
• T-cell Large Granular Lymphocytic Leukemia
• T-cell Lymphomas
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Duvelisib (duvelisib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Status: RECRUITING